1. Laboratory of Molecular Imaging, National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, MD 20892, USA.
Theranostics. 2012;2(10):999-1009. doi: 10.7150/thno.5276. Epub 2012 Oct 17.
The GLP-1 receptor plays an important role in glucose homeostasis and thus is a very important target for diabetes therapy. The receptor is also overexpressed in insulinoma, a tumor of pancreatic beta-cells. We previously evaluated two fluorine-18-labeled analogs of exendin-4 prepared by conjugation with [(18)F]FBEM (N-[2-(4-[(18)F]fluorobenzamide)ethyl]maleimide). Both compounds demonstrated good tumor uptake, but the synthesis of the radiotracers was time consuming. To overcome this challenge, we developed a NOTA analog and performed radiolabeling using aluminum [(18)F]fluoride complexation.
Cys(40)-exendin-4 was conjugated with NOTA mono N-ethylmaleimide. [(18)F]AlF conjugation was conducted and the radiolabeled product purified by preparative HPLC. Dynamic and static PET imaging scans were conducted on nude mice with established INS-1 xenografts. Uptake of tumor and other major organs in static images was quantitated (%ID/g) and comparison with blocking studies was made. PET quantification was also compared with ex vivo biodistribution results.
The radiosynthesis provided [(18)F]AlF-NOTA-MAL-cys(40)-exendin-4 in 23.6 ± 2.4 % radiochemical yield (uncorrected, n = 3) after HPLC; the process required about 55 min. The specific activity at time of injection ranged from 19.6 to 31.4 GBq (0.53-0.85 Ci)/µmol. Tumor uptake had reached its maximum (16.09 ± 1.18% ID/g, n = 4) by 5 min and remained nearly constant for the duration of the study. Kidney uptake continued to increase throughout the entire one hour time course. Pre-injection of exendin-4 caused a marked reduction in tissue uptake with the major exception of liver and kidneys, in which uptake was not affected. HPLC analysis of the radioactive components in extracts of the tumor and plasma showed primarily parent compound at 60 min post-injection, whereas extracts of kidney and urine contained exclusively one polar radioactive component.
The radiotracer is prepared in a simple one-step procedure and obtained in high specific activity after HPLC purification. [(18)F]AlF-NOTA-MAL-exendin-4 shows high tumor uptake and highly selective GLP-1 tissue uptake (INS-1 tumor, lung, pancreas), but still suffers from high kidney uptake.
GLP-1 受体在葡萄糖稳态中起着重要作用,因此是糖尿病治疗的一个非常重要的靶点。该受体在胰岛细胞瘤(胰腺 β 细胞的肿瘤)中也过度表达。我们之前评估了两种通过与 [(18)F]FBEM(N-[2-(4-[(18)F]氟苯甲酰胺)乙基]马来酰亚胺)缀合制备的 exendin-4 的氟-18 标记类似物。两种化合物均显示出良好的肿瘤摄取,但放射性示踪剂的合成耗时较长。为了克服这一挑战,我们开发了一种 NOTA 类似物,并使用铝 [(18)F] 氟化物络合物进行了放射性标记。
Cys(40)-exendin-4 与 NOTA 单 N-乙基马来酰亚胺缀合。进行 [(18)F]AlF 缀合,并通过制备型 HPLC 纯化放射性标记产物。在建立的 INS-1 异种移植的裸鼠上进行动态和静态 PET 成像扫描。在静态图像中定量测定肿瘤和其他主要器官的摄取(%ID/g),并与阻断研究进行比较。还比较了 PET 定量与离体生物分布结果。
放射性合成提供了 [(18)F]AlF-NOTA-MAL-cys(40)-exendin-4,在 HPLC 后未经校正的情况下,产率为 23.6 ± 2.4%(n = 3);该过程需要大约 55 分钟。在注射时的比活度范围为 19.6 至 31.4GBq(0.53-0.85Ci)/µmol。肿瘤摄取在 5 分钟时达到最大值(16.09 ± 1.18%ID/g,n = 4),并在整个研究期间基本保持不变。肾脏摄取在整个 1 小时的过程中持续增加。在注射前给予 exendin-4 会导致组织摄取显着减少,但主要例外是肝脏和肾脏,其摄取不受影响。肿瘤和血浆提取物中放射性成分的 HPLC 分析显示,注射后 60 分钟主要为母体化合物,而肾脏和尿液提取物仅含有一种极性放射性成分。
该示踪剂通过简单的一步法制备,并在 HPLC 纯化后获得高比活度。[(18)F]AlF-NOTA-MAL-exendin-4 显示出高肿瘤摄取和高度选择性的 GLP-1 组织摄取(INS-1 肿瘤、肺、胰腺),但仍存在高肾脏摄取。